Buparlisib

DRUG17 trials

Sponsors

Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals, Mayo Clinic, Roswell Park Cancer Institute, Anne Chang

Conditions

Adult Solid NeoplasmAdvanced or Metastatic Breast CancerBasal Cell Nevus SyndromeBreast CancerCarcinoma, Basal CellChronic Lymphocytic LeukemiaDiffuse Large B Cell LymphomaDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

Early Phase 1

Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

CompletedNCT01719250

Mayo ClinicRecurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma +2

Start: 2012-12-31End: 2017-03-22Updated: 2018-10-09

Phase 1

Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer

TerminatedNCT01820325

Novartis PharmaceuticalsNon-Small Cell Lunch Cancer

Start: 2013-09-09End: 2014-06-18Updated: 2018-10-11

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

TerminatedNCT01870726

Novartis Pharmaceuticalsc-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM

Start: 2014-01-09End: 2016-12-23Updated: 2018-05-30

Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

TerminatedNCT01911325

Novartis PharmaceuticalsSquamous Non-small Cell Lung Cancer

Start: 2013-10-31End: 2015-08-31Updated: 2018-08-14

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

CompletedNCT01934361

Novartis PharmaceuticalsRecurrent Glioblastoma Multiforme

Start: 2014-02-28End: 2016-07-07Updated: 2020-12-09

Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

WithdrawnNCT01971489

Roswell Park Cancer InstituteAdult Solid Neoplasm, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer +2

Start: 2015-09-30Updated: 2023-04-27

Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.

CompletedNCT02048787

Novartis PharmaceuticalsRenal Impairment

Start: 2014-03-31End: 2015-03-31Updated: 2020-12-09

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

CompletedNCT02154776

Novartis PharmaceuticalsAdvanced or Metastatic Breast Cancer

Start: 2014-06-27End: 2016-10-26Updated: 2020-12-19

Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

TerminatedNCT02614508

Emory UniversityRecurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia +1

Start: 2016-01-31End: 2019-08-31Updated: 2019-09-03

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

CompletedNCT02756247

Memorial Sloan Kettering Cancer CenterDiffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma +1

Start: 2016-05-09End: 2022-10-06Updated: 2022-10-10

Phase 2

Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium

CompletedNCT01551030

Memorial Sloan Kettering Cancer CenterMetastatic Transitional Cell Carcinoma of the Urothelium

Start: 2012-03-31End: 2020-09-02Updated: 2021-06-21

Safety and Efficacy of BKM120 in Relapsed and Refractory NHL

CompletedNCT01693614

Novartis PharmaceuticalsDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

Start: 2013-02-28End: 2017-07-21Updated: 2018-09-28

Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy

TerminatedNCT01852292

Novartis PharmaceuticalsHead and Neck Squamous Cell Carcinoma

Start: 2013-10-01End: 2017-03-30Updated: 2018-07-24

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

CompletedNCT01923168

Novartis PharmaceuticalsBreast Cancer

Start: 2014-03-11End: 2017-07-08Updated: 2018-09-14

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

TerminatedNCT02303041

Anne ChangBasal Cell Nevus Syndrome, Carcinoma, Basal Cell, Recurrent Skin Cancer +1

Start: 2015-02-28End: 2017-06-30Updated: 2019-01-29

Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia

CompletedNCT02340780

Canadian Cancer Trials GroupChronic Lymphocytic Leukemia

Start: 2015-04-27End: 2020-04-28Updated: 2023-08-22

Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)

University Hospital TuebingenMalignant Melanoma, Metastases

Start: 2015-07-31End: 2018-07-31Target: 22Updated: 2017-05-03

Related Papers

Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study.

2025-01-141 citations

Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

Clinical Cancer Research2021-10-0720 citations

Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study.

2020-07-0128 citations

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

Journal of Neuro-Oncology2019-11-2746 citations

Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.

Journal of Clinical Oncology2018-05-209 citations

ACTR-74. A PHASE IB/II, OPEN-LABEL, MULTICENTER STUDY OF CAPMATINIB (INC280) ALONE AND IN COMBINATION WITH BUPARLISIB (BKM120) IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA

Neuro-Oncology2017-11-011 citations

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

Haematologica2017-09-2945 citations

Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma

Neurology Genetics2017-07-1236 citations

Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL).

Journal of Clinical Oncology2017-05-204 citations

An open-label, uncontrolled, single arm phase II trial of the PI3K inhibitor buparlisib in patients with melanoma brain metastases.

Journal of Clinical Oncology2017-05-202 citations

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.

2017-01-26154 citations

Abstract 4497: NYGC glioblastoma clinical outcomes pilot study: Discovering therapeutic potential in glioblastoma through integrative genomics

Cancer Research2016-07-15

BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology2016-05-2014 citations

Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.

Journal of Clinical Oncology2016-05-2012 citations

BERIL-1: Biomarker results from targeted sequencing of circulating tumor DNA (ctDNA) and archival tissue in a randomized phase II study of buparlisib (BKM120) or placebo plus paclitaxel in patients with head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology2016-05-201 citations

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)

Blood2015-12-038 citations

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.

2015-09-01132 citations

Phase 2 study of the pan-isoform PI3 kinase inhibitor BKM120 in metastatic urothelial carcinoma patients.

Journal of Clinical Oncology2015-03-0110 citations

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma

Blood2014-12-0616 citations

Phase II, randomized, placebo-controlled study of BYL719 or buparlisib (BKM120) with letrozole for neoadjuvant treatment of postmenopausal women with HR+/HER2−, <i>PIK3CA</i> mutant or wild-type, breast cancer (BC).

Journal of Clinical Oncology2014-05-202 citations